Pharmaceutical Engineering Firm Fabtech Gears Up for IPO Debut

Fabtech Technologies, a Mumbai-based turnkey engineering solutions provider for the pharmaceutical, biotech, and healthcare industries, is gearing up for its maiden public offering. The IPO is set to open for public bidding on September 29, 2025, with the company aiming to raise ₹230 crore through a fresh issue of 1.2 crore equity shares.

Ahead of the listing, the unlisted shares of Fabtech Technologies have been trading at a premium in the grey market, with data indicating a nearly 10% increase over the IPO price. The company's comprehensive start-to-finish solutions, encompassing designing, engineering, procurement, installation, and testing of pharmaceutical equipment, have garnered significant interest from investors.

Fabtech Technologies plans to utilize the proceeds from the IPO to fund its working capital requirements, pursue inorganic growth initiatives through acquisitions, and for general corporate purposes. The company has completed 35 projects across countries, including Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka, and the UAE, until June 2024.